Mahsa Mohiti-Asli is currently Pharmaceutical Technical Manager at BASF corporation. She has a Ph.D. in Polymer Science with a minor in Biomedical Engineering and Post-doctoral Fellowship from North Carolina Biotechnology Center. She has authored numerous publications, US patents, and book chapters on Controlled Release Biomaterials for Tissue Engineering, Wound Healing, and Regenerative Medicine. Prior to joining BASF, Mahsa worked in Biotech/Pharma industry as a Formulation Scientist and Process Engineer for companies like Novozymes and Genentech. She held various positions of increasing responsibilities related to Biologics Formulation Development, Bioprocess Development for Protein-based drug products and Technology Transfer from R&D sites to pilot and manufacturing sites. Mahsa’s passion for individualized medicine goes back to when she was a graduate student working on tissue engineered scaffolds using human adipose derived stem cells (hASCs) harvested from patients who underwent liposuction. Her research was focused on differentiating those hADCs to bone and cartilage cells to be used in implantable scaffolds treating the donor’s bone or cartilage defects. Mahsa’s interest in patient-oriented therapies continued with her role at Genentech, where she learned about individualized neoantigen specific immunotherapy. At her current role, Mahsa works with many pharmaceutical companies hoping to inspire individualized medicines with BASF’s novel excipients.